C4 Therapeutics, Inc. (CCCC) KPIs and segments
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3019% above fair value
$2.77−0.12 (-4.15%)
Close on Nov 12, 2026Market cap $340.78MP/E –Yield –
KPIs & segments
Operating metrics and segments that drive C4 Therapeutics's business
Coming soon
This tab will track the numbers specific to C4 Therapeutics's business model — such as store count, revenue by banner, revenue per store and new openings — taken from filings and earnings releases.
See a number that looks wrong?